<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Nuvectra: Positioned For Growth In Neuromodulation

Posted by Anne Staylor on 5/4/17 2:00 PM

It’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company.

By Anne Staylor, Managing Editor, SmartTRAK Neuromodulation
Jan. 30, 2017

Algovita.pngIt’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company. Nuvectra dove head first into the spinal cord stimulator (SCS) market in March 2016 when it launched the Algovita Spinal Cord Stimulation System in the US. Since then, the company has been looking beyond SCS and is rapidly developing the platform to support other neurological indications, including sacral nerve stimulation and deep brain stimulation. The company is currently on track to submit for US and EU regulatory approval of its Virtis Sacral Nerve Stimulation System in early 2017, and has licensed its platform to Aleva Neurotherapeutics for use in deep brain stimulation.

Subscribe to SmartTRAK Blog.

Although Nuvectra has entered a market dominated by industry giants (Boston Scientific, Medtronic, and Abbott), Nuvectra CEO Scott Drees is not fazed at the prospect of being the David among these Goliaths, particularly given his experience taking on Medtronic when he was with Advanced Neuromodulation Systems in 1996.

But how does Nuvectra plan to compete with the big players in this space? What are the company’s strategies for growth? How is Nuvectra positioning itself in the market place? To find out the answers to these questions and more, BioMedGPS interviewed Drees at the North American Neuromodulation Society (NANS) 2017 Annual Meeting in Las Vegas in January.

 


 Interview Questions By Timecode:

0:00 It’s been almost a year since Nuvectra spun-off from Greatbatch. Can you discuss the company’s growth to date, and what your priorities have been the first year in getting established in the market?

2:28 The spinal cord stimulation market is rapidly evolving, with new technologies and waveforms. How are you positioning Nuvectra in the market place?

5:08 Sounds like you already are expanding indications, and are looking at some other neuromodulation segments and novel technologies. Anything else in the pipeline that you can discuss?

6:25 What’s next for the company?

Subscribe to Blog

Topics: Neuromodulation, Neurotherapies

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts